[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

LV12350B - HEPTAPEPHITE OXITOCIN ANALOGUE - Google Patents

HEPTAPEPHITE OXITOCIN ANALOGUE Download PDF

Info

Publication number
LV12350B
LV12350B LVP-99-77A LV990077A LV12350B LV 12350 B LV12350 B LV 12350B LV 990077 A LV990077 A LV 990077A LV 12350 B LV12350 B LV 12350B
Authority
LV
Latvia
Prior art keywords
asn
abu
mpa
ile
residue
Prior art date
Application number
LVP-99-77A
Other languages
English (en)
Latvian (lv)
Other versions
LV12350A (lv
Inventor
Per Melin
Anders Nilsson
Jerzy Trojnar
Carl-Johan Aurell
Pierre Riviere
Robert Haigh
Original Assignee
Ferring B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring B.V. filed Critical Ferring B.V.
Publication of LV12350A publication Critical patent/LV12350A/xx
Publication of LV12350B publication Critical patent/LV12350B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/16—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
LVP-99-77A 1996-11-26 1999-04-30 HEPTAPEPHITE OXITOCIN ANALOGUE LV12350B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9604341A SE9604341D0 (sv) 1996-11-26 1996-11-26 Hepta-peptide oxytocin analogue
PCT/SE1997/001968 WO1998023636A1 (en) 1996-11-26 1997-11-21 Heptapeptide oxytocin analogues

Publications (2)

Publication Number Publication Date
LV12350A LV12350A (lv) 1999-09-20
LV12350B true LV12350B (en) 1999-11-20

Family

ID=20404757

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-99-77A LV12350B (en) 1996-11-26 1999-04-30 HEPTAPEPHITE OXITOCIN ANALOGUE

Country Status (35)

Country Link
US (1) US6143722A (pl)
EP (1) EP0938496B1 (pl)
JP (1) JP3405460B2 (pl)
KR (1) KR100463132B1 (pl)
CN (1) CN1129606C (pl)
AR (1) AR008531A1 (pl)
AT (1) ATE242264T1 (pl)
AU (1) AU713424B2 (pl)
BR (1) BR9713366B1 (pl)
CA (1) CA2272990C (pl)
CZ (1) CZ299532B6 (pl)
DE (1) DE69722651T2 (pl)
DK (1) DK0938496T3 (pl)
EE (1) EE03832B1 (pl)
ES (1) ES2203823T3 (pl)
HK (1) HK1022481A1 (pl)
HR (1) HRP970630B1 (pl)
HU (1) HU228568B1 (pl)
IL (1) IL129519A (pl)
LT (1) LT4650B (pl)
LV (1) LV12350B (pl)
MY (1) MY125555A (pl)
NO (1) NO321380B1 (pl)
NZ (1) NZ336445A (pl)
PL (1) PL189292B1 (pl)
PT (1) PT938496E (pl)
RO (1) RO120772B1 (pl)
RU (1) RU2180668C2 (pl)
SE (1) SE9604341D0 (pl)
SI (1) SI20026B (pl)
SK (1) SK283800B6 (pl)
TR (1) TR199901028T2 (pl)
UA (1) UA54459C2 (pl)
WO (1) WO1998023636A1 (pl)
ZA (1) ZA9710518B (pl)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
US6476072B1 (en) * 2000-11-21 2002-11-05 Arthur Vanmoor Method of treating menstrual pain by enhancing the effectiveness of the human immune system
AU2003211011A1 (en) * 2002-02-27 2003-09-09 Ferring Bv Intermediates and methods for making heptapeptide oxytocin analogues
WO2003093816A2 (en) * 2002-05-02 2003-11-13 Bayer Healtchare Ag Diagnostics and therapeutics for diseases associated with oxytocin receptor (oxtr)
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
UA76639C2 (uk) * 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій
ES2260563T3 (es) * 2003-11-13 2006-11-01 Ferring B.V. Paquete de blister y forma farmaceutica solida para ello.
EP1555029A1 (en) 2004-01-19 2005-07-20 Ferring B.V. Use of substances having oxytocin antagonistic properties for the preparation of a medicament for treating hypertension
US20060171909A1 (en) * 2005-02-03 2006-08-03 The Procter & Gamble Company Cosmetic compositions comprising colorants with low free dye
SE0600482L (sv) * 2006-03-02 2006-11-14 Ferring Int Ct Sa Farmaceutisk sammansättning innefattande desmopressin, kiseldioxid och stärkelse
AU2008283929B2 (en) 2007-08-06 2013-10-10 Serenity Pharmaceuticals, Llc Methods and devices for desmopressin drug delivery
DK2260053T3 (da) * 2008-03-31 2014-06-23 Ferring Bv Oxytocin-analoger
PT3225250T (pt) 2008-05-21 2019-10-15 Ferring Bv Desmopressina orodispersivel para aumentar o periodo inicial de sono não perturbado pela nocturia
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
TWI463990B (zh) * 2009-09-21 2014-12-11 Ferring Bv 催產素受體促進劑
MX2013000543A (es) 2010-07-15 2013-10-28 Oleg Iliich Epshtein Un metodo para aumentar el efecto de una forma activa potenciada de un anticuerpo.
JO3400B1 (ar) * 2010-09-30 2019-10-20 Ferring Bv مركب صيدلاني من كاربيتوسين
JP6150726B2 (ja) 2011-03-09 2017-06-21 Jitsubo株式会社 新規な非ペプチド性架橋構造を含む架橋ペプチド、ならびに該架橋ペプチドの合成方法および該方法に用いる新規な有機化合物
CN102875650B (zh) * 2012-09-26 2014-06-11 深圳翰宇药业股份有限公司 巴卢西班的制备方法
US9365615B2 (en) 2013-09-09 2016-06-14 Jitsubo Co., Ltd. Cross-linked peptides containing non-peptide cross-linked structure, method for synthesizing cross-linked peptides, and novel organic compound used in method
PL3037101T3 (pl) * 2014-12-22 2019-06-28 Ferring B.V. Terapia antagonistą receptora oksytocyny w fazie lutealnej w celu implantacji i uzyskania ciąży u kobiet poddawanych technikom wspomaganego rozrodu
US9744239B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US20180282367A1 (en) 2015-10-06 2018-10-04 Ferring B.V. New methods for making barusiban and its intermediates
EA036990B1 (ru) 2016-01-04 2021-01-25 Мерк Сероно С.А. (3s)-3-({[(2s)-3-(бифенил-4-илсульфонил)-1,3-тиазолидин-2-ил]карбонил}амино)-3-(4-фторфенил)пропил l-валинат и его солевая форма, кристаллический полиморф
MA52548A (fr) 2016-07-21 2021-05-26 ObsEva SA Régimes posologiques d'antagonistes de l'ocytocine pour favoriser l'implantation d'embryons et prévenir les fausses couches
CN114667141A (zh) 2019-09-03 2022-06-24 奥布赛瓦股份公司 用于促进胚胎移植和预防流产的催产素拮抗剂给药方案
AU2021218895A1 (en) 2020-02-10 2022-09-15 ObsEva S.A. Biomarkers for oxytocin receptor antagonist therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2036973A1 (en) * 1990-02-27 1991-08-28 Mark G. Bock Cyclic hexapeptide oxytocin antagonists
SE9002384D0 (sv) * 1990-07-09 1990-07-09 Ferring Ab Derivat av baklobshormoner
SE501678C2 (sv) * 1993-07-13 1995-04-10 Ferring Bv Peptid med oxytocinantagonistaktivitet samt farmaceutisk komposition innehållande nämnda peptid
SE523819C2 (sv) 1994-01-27 2004-05-18 Per-Ingvar Nilsson Accelerationsmunstycke samt metod för dess användning
SE9400918L (sv) 1994-03-18 1995-09-19 Anne Fjellstad Paulsen Stabiliserad komposition för oral administrering av peptider
SE9500249L (sv) 1995-01-25 1996-03-25 Valeo Engine Cooling Ab Värmeväxlartank med ändstycken, förfarande för framställning av en sådan tank, samt värmeväxlare försedd med en sådan

Also Published As

Publication number Publication date
IL129519A (en) 2004-09-27
HRP970630B1 (en) 2002-04-30
CN1129606C (zh) 2003-12-03
KR20000069045A (ko) 2000-11-25
BR9713366B1 (pt) 2010-05-18
MY125555A (en) 2006-08-30
CZ299532B6 (cs) 2008-08-27
ATE242264T1 (de) 2003-06-15
NZ336445A (en) 2000-06-23
KR100463132B1 (ko) 2004-12-23
HUP0000577A3 (en) 2001-02-28
EP0938496B1 (en) 2003-06-04
RO120772B1 (ro) 2006-07-28
ZA9710518B (en) 1998-06-10
JP2000507617A (ja) 2000-06-20
HK1022481A1 (en) 2000-08-11
CA2272990A1 (en) 1998-06-04
US6143722A (en) 2000-11-07
LT4650B (lt) 2000-04-25
NO321380B1 (no) 2006-05-02
LT99052A (en) 2000-01-25
EE03832B1 (et) 2002-08-15
PT938496E (pt) 2003-10-31
NO992532D0 (no) 1999-05-26
HRP970630A2 (en) 1998-10-31
HUP0000577A2 (hu) 2000-11-28
ES2203823T3 (es) 2004-04-16
SE9604341D0 (sv) 1996-11-26
RU2180668C2 (ru) 2002-03-20
SK283800B6 (sk) 2004-02-03
NO992532L (no) 1999-05-26
IL129519A0 (en) 2000-02-29
CN1238781A (zh) 1999-12-15
PL189292B1 (pl) 2005-07-29
DK0938496T3 (da) 2003-10-06
HU228568B1 (en) 2013-04-29
AR008531A1 (es) 2000-01-19
DE69722651T2 (de) 2004-04-08
EE9900210A (et) 1999-12-15
SI20026B (sl) 2000-06-30
CZ183299A3 (cs) 2000-05-17
EP0938496A1 (en) 1999-09-01
TR199901028T2 (xx) 1999-07-21
DE69722651D1 (en) 2003-07-10
JP3405460B2 (ja) 2003-05-12
BR9713366A (pt) 2000-01-25
AU5142998A (en) 1998-06-22
LV12350A (lv) 1999-09-20
SI20026A (sl) 2000-02-29
UA54459C2 (uk) 2003-03-17
WO1998023636A1 (en) 1998-06-04
SK70499A3 (en) 2000-10-09
AU713424B2 (en) 1999-12-02
CA2272990C (en) 2002-11-19

Similar Documents

Publication Publication Date Title
EP0938496B1 (en) Heptapeptide oxytocin analogues
FI92326C (fi) LHRH:n nonapeptidi- ja dekapeptidianalogeja, jotka ovat käyttökelpoisia LHRH:n antagonisteina
FI104252B (fi) Menetelmä terapeuttisesti käyttökelpoisten peptidien kemialliseksi syntetisoimiseksi kiinteässä faasissa
HRP980197A2 (en) GnRH ANTAGONISTS
EP0672055A1 (en) Neuropeptide y antagonists
NO854645L (no) Fremgangsmaate for fremstilling av basiske cykliske peptider.
EP0683792A1 (en) Lhrh antagonists having modified aminoacyl residues at postions 5 and 6
CA2405704C (en) Bombesin analogs for treatment of cancer
NZ233795A (en) Derivatives of atrial natriuretic peptide (anp)
AU718192B2 (en) Peptide derivatives
AU8225191A (en) Derivatives of pituitary posterior lobe hormones
US5071836A (en) Competitive gonadoliberin antagonists
TW386086B (en) Heptapeptide oxytocin analogues
JPS62209096A (ja) バソプレシン化合物
EP0791012A1 (en) Peptides exhibiting oxytocin antagonistic activity